The ribavirin analog ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of hepatitis-induced serum alanine aminotransferase levels.
The demonstrated utility of the nucleoside analog ribavirin in the treatment of certain viral diseases can be ascribed to its multiple distinct properties. These properties may vary in relative importance in differing viral disease conditions and include the direct inhibition of viral replication, the promotion of T-cell-mediated immune responses via an enhanced type 1 cytokine response, and a reduction of circulating alanine aminotransferase (ALT) levels associated with hepatic injury. Ribavirin also has certain known toxicities, including the induction of anemia upon chronic administration. To determine if all these properties are linked, we compared the D-nucleoside ribavirin to its L-enantiomer (ICN 17261) with regard to these properties. Strong similarities were seen for these two compounds with respect to induction of type 1 cytokine bias in vitro, enhancement of type 1 cytokine responses in vivo, and the reduction of serum ALT levels in a murine hepatitis model. In contrast, ICN 17261 had no in vitro antiviral activity against a panel of RNA and DNA viruses, while ribavirin exhibited its characteristic activity profile. Importantly, the preliminary in vivo toxicology profile of ICN 17261 is significantly more favorable than that of ribavirin. Administration of 180 mg of ICN 17261 per kg of body weight to rats by oral gavage for 4 weeks generated substantial serum levels of drug but no observable clinical pathology, whereas equivalent doses of ribavirin induced a significant anemia and leukopenia. Thus, structural modification of ribavirin can dissociate its immunomodulatory properties from its antiviral and toxicologic properties, resulting in a compound (ICN 17261) with interesting therapeutic potential.
Tam
R C
RC
Immunology, ICN Research Department, ICN Pharmaceuticals, Inc., Costa Mesa, California 92626, USA. rctam@icnpharm.com
Ramasamy
K
K
Bard
J
J
Pai
B
B
Lim
C
C
Averett
D R
DR
D000410:Alanine Transaminase / Q000097:blood*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood* / Q000188:drug therapy / Q000201:enzymology; D003208:Concanavalin A; D016207:Cytokines / Q000096:biosynthesis / Q000276:immunology; D005260:Female; D006678:HIV / Q000187:drug effects; D006518:Hepatitis Viruses / Q000187:drug effects; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D051381:Rats; D012254:Ribavirin / Q000627:therapeutic use / Q000633:toxicity*; D013237:Stereoisomerism; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000998:Antiviral Agents; D016207:Cytokines; D003208:Concanavalin A; D012254:Ribavirin; D000410:Alanine Transaminase